Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Inhibikase Therapeutics Inc IKT

Healthcare Biotechnology
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson’s disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate. The Company’s RAMP medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain.


NDAQ:IKT - Post by User

Inhibikase Therapeutics Inc
<< Previous
 Bullboard Posts
User Avatar Image
(200)
•••
Post by whytestockson Oct 21, 2024 12:18pm
7 Views
Post# 36274941

Inhibikase Therapeutics Announces Closing of up to $275 Mill

Inhibikase Therapeutics Announces Closing of up to $275 Mill
Just In: $IKT Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension-- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and 60&#xA0;-- BOSTON and ATLANTA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc....IKT - Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities